HUTCHMED

— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance in the advanced setting

Total Voting Rights

Blocklisting Six Monthly Return

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

Monthly Return

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

Total Voting Rights

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

List of Directors and Their Roles and Functions

Annual General Meeting held on May 13, 2025 – Poll Results

Monthly Return

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

Annual General Meeting 2025

2024 Annual Report and Notice of Annual General Meeting

Monthly Return

Extraordinary General Meeting held on March 31, 2025 – Poll Results

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

OVERSEAS REGULATORY ANNOUNCEMENT: Publication of Form 20-F

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

Adoption of the 2025 Long Term Incentive Plan

Vesting of Awards under the Long Term Incentive Plan

Extraordinary General Meeting (March 31, 2025)

List of Directors and Role and Function

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Monthly Return

Overseas Regulatory Announcement – Update on Transaction

Overseas Regulatory Announcement – Update on Transaction

HUTCHMED to Announce 2024 Final Results

List of Directors and Their Roles and Functions

Monthly Return

Overseas Regulatory Announcement – Disposal Transaction

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Monthly Return

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

Major Transaction in Relation to The Disposal of 45% Equity Interest in Shanghai Hutchison Pharmaceuticals Limited

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

Appointment of Cavendish as Joint Corporate Broker in London

Blocklisting Six Monthly Return

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

Monthly Return

Total Voting Rights

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED Announces China Approval for ORPATHYS^® in Combination with TAGRISSO^® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK^® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS^® and TAGRISSO^® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA^® (fruquintinib)

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS^® and TAGRISSO^® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE^® (Fruquintinib) in Combination with TYVYT^® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

HUTCHMED Announces Continued Inclusion of ORPATHYS^® (savolitinib) in the National Reimbursement Drug List in China at Current Terms